Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
NCT03933319Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Duomeisu in HER2-positive breast cancer, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
Duomeisu
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03933319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933319.